O	0	10	Randomised
O	11	21	controlled
O	22	27	trial
O	28	30	of
B-intervention	31	39	exercise
O	40	42	to
O	43	50	prevent
B-condition	51	59	shoulder
I-condition	60	68	problems
O	69	71	in
B-eligibility	72	77	women
I-eligibility	78	88	undergoing
I-eligibility	89	95	breast
I-eligibility	96	102	cancer
I-eligibility	103	112	treatment
O	112	113	:
O	114	119	study
O	120	128	protocol
O	129	132	for
O	133	136	the
O	137	147	prevention
O	148	150	of
O	151	159	shoulder
O	160	168	problems
O	169	174	trial
O	175	176	(
O	176	178	UK
O	179	186	PROSPER
O	186	187	)
O	187	188	.

O	189	204	Musculoskeletal
O	205	213	shoulder
O	214	222	problems
O	223	226	are
O	227	233	common
O	234	239	after
O	240	246	breast
O	247	253	cancer
O	254	263	treatment
O	263	264	.

O	265	270	Early
O	271	284	postoperative
O	285	294	exercises
O	295	304	targeting
O	305	308	the
O	309	314	upper
O	315	319	limb
O	320	323	may
O	324	331	improve
O	332	340	shoulder
O	341	349	function
O	349	350	.

O	351	355	This
O	356	364	protocol
O	365	374	describes
O	375	376	a
O	377	385	National
O	386	395	Institute
O	396	399	for
O	400	406	Health
O	407	415	Research
O	415	416	-
O	416	422	funded
O	423	433	randomised
O	434	444	controlled
O	445	450	trial
O	451	452	(
O	452	455	RCT
O	455	456	)
O	457	459	to
O	460	468	evaluate
O	469	472	the
O	473	481	clinical
O	482	485	and
O	486	490	cost
O	490	491	-
O	491	504	effectiveness
O	505	507	of
O	508	510	an
O	511	516	early
O	517	527	supervised
O	528	538	structured
O	539	547	exercise
O	548	557	programme
O	558	566	compared
O	567	571	with
O	572	577	usual
O	578	582	care
O	582	583	,
O	584	587	for
O	588	593	women
O	594	596	at
O	597	601	high
O	602	606	risk
O	607	609	of
O	610	620	developing
O	621	629	shoulder
O	630	638	problems
O	639	644	after
O	645	651	breast
O	652	658	cancer
O	659	666	surgery
O	666	667	.

O	668	672	This
O	673	682	pragmatic
O	683	686	two
O	686	687	-
O	687	692	armed
O	692	693	,
O	694	705	multicentre
O	706	709	RCT
O	710	712	is
O	713	721	underway
O	722	728	within
O	729	738	secondary
O	739	743	care
O	744	746	in
O	747	750	the
O	751	753	UK
O	753	754	.

O	755	765	PRevention
O	766	768	Of
O	769	777	Shoulder
O	778	786	ProblEms
O	787	792	tRial
O	793	794	(
O	794	801	PROSPER
O	801	802	)
O	803	807	aims
O	808	810	to
O	811	818	recruit
B-total-participants	819	822	350
O	823	828	women
O	829	833	from
O	834	847	approximately
O	848	850	15
B-location	851	853	UK
O	854	861	centres
O	862	866	with
O	867	873	follow
O	873	874	-
O	874	876	up
O	877	879	at
O	880	881	6
O	882	887	weeks
O	887	888	,
O	889	890	6
O	891	894	and
O	895	897	12
O	898	904	months
O	905	910	after
O	911	924	randomisation
O	924	925	.

O	926	937	Recruitment
O	938	947	processes
O	948	951	and
O	952	964	intervention
O	965	976	development
O	977	981	were
O	982	991	optimised
O	992	999	through
O	1000	1011	qualitative
O	1012	1020	research
O	1021	1027	during
O	1028	1029	a
O	1030	1031	6
O	1031	1032	-
O	1032	1037	month
O	1038	1046	internal
O	1047	1052	pilot
O	1053	1058	phase
O	1058	1059	.

O	1060	1072	Participants
O	1073	1076	are
O	1077	1087	randomised
O	1088	1090	to
O	1091	1094	the
O	1095	1102	PROSPER
O	1103	1115	intervention
O	1116	1118	or
O	1119	1123	best
O	1124	1132	practice
B-control	1133	1138	usual
I-control	1139	1143	care
I-control	1144	1148	only
O	1148	1149	.

O	1150	1153	The
O	1154	1161	PROSPER
O	1162	1174	intervention
O	1175	1177	is
O	1178	1187	delivered
O	1188	1190	by
O	1191	1207	physiotherapists
O	1208	1211	and
O	1212	1224	incorporates
O	1225	1230	three
O	1231	1235	main
O	1236	1246	components
O	1246	1247	:
O	1248	1256	shoulder
O	1256	1257	-
O	1257	1265	specific
O	1266	1275	exercises
O	1276	1285	targeting
O	1286	1291	range
O	1292	1294	of
O	1295	1303	movement
O	1304	1307	and
O	1308	1316	strength
O	1316	1317	;
O	1318	1325	general
O	1326	1334	physical
O	1335	1343	activity
O	1344	1347	and
O	1348	1359	behavioural
O	1360	1370	strategies
O	1371	1373	to
O	1374	1383	encourage
O	1384	1393	adherence
O	1394	1397	and
O	1398	1405	support
O	1406	1414	exercise
O	1415	1424	behaviour
O	1424	1425	.

O	1426	1429	The
O	1430	1437	primary
O	1438	1445	outcome
O	1446	1448	is
B-outcome-Measure	1449	1454	upper
I-outcome-Measure	1455	1458	arm
I-outcome-Measure	1459	1467	function
O	1468	1476	assessed
O	1477	1482	using
O	1483	1486	the
O	1487	1499	Disabilities
O	1500	1502	of
O	1503	1506	the
O	1507	1510	Arm
O	1510	1511	,
O	1512	1520	Shoulder
O	1521	1524	and
O	1525	1529	Hand
O	1530	1531	(
O	1531	1535	DASH
O	1535	1536	)
O	1537	1550	questionnaire
O	1551	1553	at
O	1554	1556	12
O	1557	1563	months
O	1564	1581	postrandomisation
O	1581	1582	.

O	1583	1592	Secondary
O	1593	1601	outcomes
O	1602	1609	include
B-outcome-Measure	1610	1614	DASH
I-outcome-Measure	1615	1624	subscales
O	1624	1625	,
B-outcome-Measure	1626	1631	acute
I-outcome-Measure	1632	1635	and
I-outcome-Measure	1636	1643	chronic
I-outcome-Measure	1644	1648	pain
O	1648	1649	,
B-outcome-Measure	1650	1663	complications
O	1663	1664	,
B-outcome-Measure	1665	1671	health
I-outcome-Measure	1671	1672	-
I-outcome-Measure	1672	1679	related
I-outcome-Measure	1680	1687	quality
I-outcome-Measure	1688	1690	of
I-outcome-Measure	1691	1695	life
O	1696	1699	and
B-outcome-Measure	1700	1710	healthcare
I-outcome-Measure	1711	1719	resource
I-outcome-Measure	1720	1723	use
O	1723	1724	.

O	1725	1727	We
O	1728	1732	will
O	1733	1742	interview
O	1743	1744	a
O	1745	1754	subsample
O	1755	1757	of
O	1758	1760	20
O	1761	1773	participants
O	1774	1776	to
O	1777	1784	explore
O	1785	1790	their
O	1791	1802	experiences
O	1803	1805	of
O	1806	1809	the
O	1810	1815	trial
O	1816	1829	interventions
O	1829	1830	.

O	1831	1834	The
O	1835	1842	PROSPER
O	1843	1848	study
O	1849	1851	is
O	1852	1855	the
O	1856	1861	first
O	1862	1873	multicentre
O	1874	1876	UK
O	1877	1885	clinical
O	1886	1891	trial
O	1892	1894	to
O	1895	1906	investigate
O	1907	1910	the
O	1911	1919	clinical
O	1920	1923	and
O	1924	1928	cost
O	1928	1929	-
O	1929	1942	effectiveness
O	1943	1945	of
O	1946	1955	supported
O	1956	1964	exercise
O	1965	1967	in
O	1968	1971	the
O	1972	1982	prevention
O	1983	1985	of
O	1986	1994	shoulder
O	1995	2003	problems
O	2004	2006	in
O	2007	2011	high
O	2011	2012	-
O	2012	2016	risk
O	2017	2022	women
O	2023	2033	undergoing
O	2034	2040	breast
O	2041	2047	cancer
O	2048	2055	surgery
O	2055	2056	.

O	2057	2060	The
O	2061	2069	findings
O	2070	2074	will
O	2075	2081	inform
O	2082	2088	future
O	2089	2097	clinical
O	2098	2106	practice
O	2107	2110	and
O	2111	2118	provide
O	2119	2127	valuable
O	2128	2135	insight
O	2136	2140	into
O	2141	2144	the
O	2145	2149	role
O	2150	2152	of
O	2153	2166	physiotherapy
O	2166	2167	-
O	2167	2176	supported
O	2177	2185	exercise
O	2186	2188	in
O	2189	2195	breast
O	2196	2202	cancer
O	2203	2217	rehabilitation
O	2217	2218	.

O	2219	2226	Version
O	2227	2228	2
O	2228	2229	.
O	2229	2230	1
O	2230	2231	;
O	2232	2237	dated
O	2238	2240	11
O	2241	2248	January
O	2249	2253	2017
O	2254	2259	TRIAL
O	2260	2272	REGISTRATION
O	2273	2279	NUMBER
O	2279	2280	:
O	2281	2295	ISRCTN35358984
O	2295	2296	;
O	2297	2300	Pre
O	2300	2301	-
O	2301	2308	results
O	2308	2309	.
